CYP2C19 and ischemic stroke: Given that there is a proposed mechanism that PPIs could interact with metabolic enzymes like CYP2C19, which could potentially reduce the cardiovascular benefit from antithrombotic [50, 51], further analyses need to be conducted to explore the role of antithrombotic drugs in the risk of ischaemic stroke among PPI users.